Ovid Therapeutics Transfers Stock to Nasdaq Capital Market

Ovid Therapeutics ( (OVID) ) has provided an update.

Ovid Therapeutics received approval to transfer its common stock to the Nasdaq Capital Market, providing an additional 180 days to meet the minimum bid price requirement. The company is progressing with its clinical trials, including the OV329 Phase 1 study, and has signed a $7 million royalty monetization agreement to strengthen its financial position. Ovid’s cash reserves are expected to support operations into the second half of 2026, as it continues to explore strategic options to accelerate development and manage costs.

The most recent analyst rating on (OVID) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Ovid Therapeutics stock, see the OVID Stock Forecast page.

Spark’s Take on OVID Stock

According to Spark, TipRanks’ AI Analyst, OVID is a Neutral.

Ovid Therapeutics’ overall stock score is influenced significantly by financial performance challenges, including inconsistent revenue and ongoing losses, which weigh down the score. The technical analysis offers a more positive view with upward momentum and neutral RSI, contributing positively. Valuation remains a concern due to negative earnings. The absence of earnings call data and corporate events leaves these areas without impact on the score.

To see Spark’s full report on OVID stock, click here.

More about Ovid Therapeutics

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small molecule medicines for brain conditions with significant unmet needs. The company is advancing its pipeline with several key readouts anticipated in the near and mid-term, including potential treatments for conditions driven by excess neuronal excitation, such as treatment-resistant seizures and pain.

Average Trading Volume: 1,558,455

Technical Sentiment Signal: Sell

Current Market Cap: $38.9M

See more insights into OVID stock on TipRanks’ Stock Analysis page.